UK markets open in 7 hours 46 minutes

Biogen Inc. (BIIB.MX)

Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
4,021.000.00 (0.00%)
At close: 12:29PM CDT
Sign in to post a message.
  • A
    AGBISIT
    Are you guys part of (http://traderspot.club)? They just talked about BIIB
  • d
    demetrios
    It will be acquired for 300
  • d
    demetrios
    Market cap is under 30 billion. No debt and cash and multiple drugs. There are at least 5 big pharmas that could easily buy this company. If their Alzheimer’s succeeds this stock is 500 dollars a share. They hqve the best shot for success in that field. Lilly can easily buy them. Market cap of Lilly is 300 billion. Over 10 times
  • D
    Dave
    Cheapest and best biotech. Any hint of positive news about the Alzheimer’s drug and it will be 400
  • d
    demetrios
    The roche Alzheimer’s failure is very very positive for biogen drug because of a different mechanism
  • A
    Ah Lek
    TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces that TauRx Pharmaceuticals Ltd. (“TauRx”), a leader in tau-based research in Alzheimer’s, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx’s official announcement, please visit:

    https://ts-assets.ams3.cdn.digitaloceanspaces.com/mg/tx/pdfs/Lucidity-Data-Announcement.31May2022.for-website.pdf

    TauRx Announcement Highlights:

    LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (“HMTM”) decline at a rate substantially less than is typical in Alzheimer’s based on published research.

    Safety profile is favourable and consistent with previous HMTM studies.

    TauRx will now pursue regulatory submission and coverage for HMTM.

    TauRx reports their lead investigative oral drug, HMTM, was tested in 598 people afflicted with Alzheimer’s. TauRx announced participants of the 12-month blinded phase of the study have moved to an additional one-year open label phase.

    According to TauRx’s announcement, Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx, commented: “The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies”.
  • A
    Ah Lek
    TauRx has already won the race for a disease modifying AD drug. Amyloid hypothesis has been a scam for the past 30 years.

    https://ts-assets.ams3.cdn.digitaloceanspaces.com/mg/tx/pdfs/Lucidity-Data-Announcement.31May2022.for-website.pdf
  • d
    demetrios
    Cheapest and best biotech. Any hint of positive news about the Alzheimer’s drug and it will be 400
  • J
    JessieJames
    Going below 100 now.
  • R
    RNB
    Was the after hours trade at $200 due to options being exercised after hour?

    What was the volume of trading after hours on May 27, 2022?
  • d
    demetrios
    If anything positive happens about the Alzheimer’s drug, this stock will be 400 in no time
  • D
    DigitalRobberBarons
    I'm mostly cash but hanging out in these beat up pharma names. If they pop I'll take some off the table, but I'm sure people still have to buy drugs during inflation, deflation, recession, etc... I think consolidation is still going to happen in this industry and BIIB is at a value that makes them a target.
  • G
    Guy
    this knife Is probably on the floor so I'm buying 250 shares at this price and more if at a later date if it gets pushed down with the market. I've traded it before so these shares are free from the last run. when this stock runs 🏃‍♂️next it will jump big
  • T
    Turbopicks
    (BIVI) MC 71 m...3x Blockbusters in Pipeline targeting Alzheimer Disease (Phase 3 data in mid 2023) and Parkinsons Disease (Phase 2 data coming this quarter) (Slide Presentation below)=10 Bagger opp
    https://bioviepharma.com/wp-content/uploads/2022/04/BioVie-Company-Overview-2022-04-13.pdf

    #+#+
  • b
    brando
    like that dip to 188 before the jump the algos always do that
  • d
    demetrios
    This stock market cap is only 30 billion. I don’t think it will last long as independent. Any good news about Alzheimer’s and it is a double and triple
  • d
    demetrios
    Pfizer bought a nothing company for 12 billion. Biogen is definitely a target.
  • d
    demetrios
    There is speculation that merck might be interested in acquiring biogen. Now that the CEO is leaving, that might become a reality
  • P
    Puff Pastry
    Biogen giving up on its Alzheimer’s drug was a smart move for the company. They will likely look to buying a company like Cassava Sciences that has the holy grail of Alzheimer’s drugs ..